Cases & Deals

Celgene files Hatch-Waxman suit against Mylan over Focalin XR® patents

Clients Celgene Corporation

Jones Day represented Celgene Corporation in a Hatch-Waxman patent infringement action against Mylan Pharmaceuticals concerning a generic version of Celgene’s branded drug Focalin XR®. This matter concluded through a settlement on mutually agreeable terms.

Celgene Corporation et al. v. Mylan Pharmaceuticals, Inc., Civil Action No. 2-11-cv-01882 (D.N.J.) (Judge Arleo)

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.